More sales channels increase our growth opportunities but the year got off to a weak start

January 1 - March 31, 2013

$\bullet$ Net sales were SEK 33.8 million (40.4).
Operating profit was SEK-0.7 million (5.4).
Profit before tax was SEK -1.5 million (4.4).
Earnings per share were SEK-0.06 (0.11).
Cash and cash equivalents at the close of the quarter were SEK 52.5 million (56.5).
CellaVision signs an agreement with one more distribution partner in Europe Abbott.
New product for quality assurance launched CellaVision® Proficiency Software.

Significant events after the period close

CellaVision and Beckman Coulter increased their cooperation by adding EMEA to their global distribution agreement. The agreement entered into force on April 8, 2013.
On April 16 CellaVision and Sysmex published the news of a jointly developed product, the DI-60, for laboratories in hematology. CellaVision's digital image analysis technology has been integrated with Sysmex cell counters and sample preparation instruments.
On April 19 Magnus Blixt was appointed new CFO, taking up his position on May 2, 2013.

Key ratios

(SEK million)	Jan-March Jan-March 2013	2012	Full year 2012
Net sales	33.8	40.4	169.5
Gross profit or loss	22.0	27.1	110.1
Operating profit	$-0.7$	5.4	20.7
Operating margin, %	Neg.	13.4	12.2
Profit/loss before tax	$-1.5$	4.4	18.6
Cash flow for the period	6.3	$-0.3$	$-10.6$

Comments by CellaVision's CEO Yvonne Mårtensson:

"The subdued demand for medical devices we experienced at the end of 2012 has continued into 2013. In the year's first quarter our sales were lower in our main markets, Europe and North America, and we report negative earnings. Fortunately enough, our sales are strong in the Asia & Pacific region, which is a result of determined market penetration in the region. The region is an important growth market for us.

In 2013 several business transactions have taken place that are of very great significance for CellaVision's future development. Siemens started selling globally and received its first order in Europe. In Europe we broadened our sales channels at the same time by signing agreements with Beckman Coulter and Abbott. In most geographical markets we now cooperate with four of the five major players, which increases CellaVision's visibility and growth potential.

For the first time we are integrating our world-leading technology with a partner's product. The product is the result of a long-standing sound partnership with Sysmex but also a natural development of the product offer to the hematology market, in which automation is an important factor behind increased effectiveness. The DI-60 will keep CellaVision at the leading edge of its area of technology. As part of our cost effectiveness strategy the product was developed on our primary hardware platform, CellaVision DM1200.

Interest in our products and our position in the market has never been stronger. However, the continuing weak world economy is delaving the hospital laboratories' purchases of equipment which impacts on our distributors' demand. Uncertainty in the market affects us and we expect lower income and negative earnings also in the second quarter. Looking ahead. Hook forward with confidence to the results of our new products and broad distribution channels."

Net sales $-16%$

Operating profit SEK-0.7

"The DI-60 is a natural development of the product offer to the hematology market."

Yvonne Mårtensson, CEO of CellaVision AB

Sales, earnings and investments

January 1 - March 31

Net sales for the Group in the first quarter of 2013 were SEK 33.8 million (40.4), a decrease of 16% compared with the same period in 2012.

Sales in international markets are mainly in USD and EUR, which means that the company's sales and results are impacted by changes in these currencies. The company hedges 50-75 per cent of planned currency flows to compensate for any foreign exchange fluctuations.

The gross margin for the quarter was 65 % (67). CellaVision usually has large gross margin variations from quarter to quarter. This is dependent on the share of sales via distributors or via CellaVision's own sales companies, the product mix and exchange rates.

The Group's operating profit for the quarter was SEK-0.7 million (5.4).

Total operating expenses for the quarter were SEK 22.7 million (21.7).

CellaVision is conducting several development projects, aimed at strengthening the product portfolio in relation to customers in the field of hematology. Capitalized expenditure for development projects was SEK 2.6 million (1.4) for the quarter.

Investments in property, plant and equipment during the quarter amounted to SEK 0.8 million $(0.4)$ .

Sales per quarter and rolling 12 months (SEK million)

Net sales SEK 33.8

Development in geographical markets

In the period January-March Europe accounted for the greatest share of sales, 42 % (37), North America for 32 % (58), and Asia and the Pacific region for 26 % (5). Growth in the Asia & Pacific region refers to analyzer sales in Japan and Taiwan, and the purchase by the Sysmex Corporation of the new DI-60 product for internal training and launch preparations.

Like others in the medical devices industry selling capital equipment, CellaVision's inflow of orders is unevenly distributed over the year, depending on distributors' sales, inventory levels and contracted volumes. Consequently, the variation in order volume in individual quarters may be great in the different geographical markets.

Net sales per geographical market, SEK million

North America

The downturn we saw in the North American market at the end of 2012 continued into the first quarter of this year. Compared with the corresponding period in 2012, sales in the USA and Canada fell by more than half, both in SEK and local currency and were SEK 10.8 million $(23.5)$ .

Growth has slowed, mainly due to lengthy decision-making processes resulting in a prolonged sales cycle. There is still great uncertainty about coming political decisions in the USA. This also affects Canada, since the economy there normally lags slightly behind the USA in the economic cycle.

In the USA CellaVision works with several distribution channels, which effectively improves the company's expansion potential in the market: Sysmex, Beckman Coulter, our own sales organization and, since January 1, 2013 with Siemens as well. Together with the distributors CellaVision has high visibility in the market. By means of a co-marketing agreement, the company also works closely with the fourth largest player, Abbott.

In the first quarter, partnership with Siemens got going in that CellaVision's salespeople participated in Siemens product demonstrations at customer sites, as well as in several of the company's recurrent customer events around the USA, called "Diagnostic Days".

The first order for the Citrix adapted software for remote access, CellaVision® Remote Review Software Citrix, was delivered during the quarter to an American hospital laboratory. The product enables the customer to allow staff outside the laboratory to examine test results and give an opinion without leaving their physical location. The product was installed in the customer's Citrix environment, which is applied for software distribution and IT administration.

First order for remote access software in a Citrix environment

During the quarter a new product for internal and external quality assurance of laboratory analyses was introduced; CellaVision® Proficiency Software. The product targets hospital and other laboratories that assess and conduct classification of blood cells and external quality bodies that arrange tests in laboratory medicine. The product's potential savings in both time and money is creating interest in both customer groups. The product exists in two software versions. Enterprise and Professional, and is sold directly by CellaVision AB on the basis of an annual license fee.

Europe, the Middle East and Africa (EMEA)

Investments in medical devices continued to be affected by the generally tough economic climate in Europe and uncertainty about health care budgets and investment decisions. The region's sales in the first quarter of the year were SEK 14.2 million (15.0), a decrease of about 5 per cent in SEK and local currencies.

To increase the company's chances of participating with its products in procurements of laboratory equipment in European countries, in 2013 CellaVision broadened its sales channels with Abbott and Beckman Coulter. In EMEA CellaVision has been working together with Sysmex since 2001 and with Siemens since January 1, 2013. The distributors are the four major suppliers of cell counters in the European market.

There has been great focus during the quarter on starting training of the new distributors Siemens and Abbott. During the quarter Siemens sales activities started in the European market.

The new product for internal and external quality assurance of laboratory analyses, CellaVision® Proficiency Software, has aroused interest among both hospital laboratories and external quality bodies around Europe. During the quarter the product was evaluated by the Swedish quality body Equalis, with favourable results.

Asia and the Pacific region

Marketing in Asia and the Pacific region is in process of being built up. In the first quarter of the year sales in the region increased to SEK 8.8, (1.9), which can be attributed to sales of analyzers in Japan and Taiwan. In local currencies sales almost quadrupled. CellaVision assesses that in the long term, above all the markets in China, South East Asia and Japan will have the potential for strong development.

In China CellaVision's solution will be marketed to hospitals with more than 500 beds that conduct training and research. CellaVision's main focus is to support our distributors' efforts to build awareness and acceptance of the Company's products in the Chinese market.

Sales to Japan during the guarter refer to several CellaVision DM96 analyzers and the purchase by the Sysmex Corporation of the new DI-60 product for internal training. We can see increased interest in CellaVision's solutions in the Japanese market and see a potential in the DI-60 that is integrated into the Sysmex product line. In parallel with Sysmex, CellaVision's own sales organization is continuing to increase knowledge and interest in CellaVision's products, for example through presentations of customers' study results at seminars and industry fairs.

First Siemens sale

Increased interest in Japan

Research h and dev velopmen nt

CellaVision is portfolio in r s conducting relation to cus several deve stomers in th lopment proj e field of hem jects, aimed a matology. at strengtheni ing the produ uct

During the q analyses, Ce server and ad any compute aimed at ma quarter the ne llaVision® Pro dapted to org er at all witho aking quality c ew product fo oficiency Softw ganizations w out download control easier or internal and ware, was com with many use ding software. r and more eff d external qua mpleted. The ers, which me . When design ffective. ality assuranc program is lo ans that they ning the prog ce of laborato ocated in a clo can be run fr gram CellaVisi ory oud rom ion

The new pro internal eval image analys developed o customer the the analysis oduct, the DI-6 uations and l sis technolog on CellaVision e solution me process. 60, developed aunching pre gy with the Sy n's primary ha eans that man d in partnersh eparations. Th ysmex XN seri rdware platfo nual processin hip with Sysm he new produ es for automa orm, CellaVisio ng of samples mex, was ready uct integrates ated blood an on DM1200. F s completely d y for Sysmex' CellaVision's nalysis. It was For the end disappears fro om

CellaVision c capitalized e company ass million in the continuously expenditure fo sesses that ca e 2013 financ capitalizes co or developme apitalized exp cial year. osts for new d ent projects a penditure for n evelopment. amounted to S new develop During the q SEK 2.6 millio ment will tota uarter n (1.4). The al about SEK 9

Significa ant event ts after th he period close

In April 2013 distribution partnership w Nordic coun a broader re into force on 3 CellaVision e agreement fo with Beckma tries, Canada ach and can m n April 8, 2013 extended its c or the countri n Coulter now and Japan. W more quickly 3. cooperation w es of Europe, w covers the e With parallel s create interes with Beckman , the Middle E entire world w ales channels st in its produ n Coulter by s East and Africa with the exce s in the region ucts. The agre igning a a. The ption of the n CellaVision h ement came 9has

On April 16 C developed a counters and global produ that already planning to Milan, Italy, o CellaVision an a product by i d sample prep uct portfolio f have the ana present the p on May 19-23 nnounced tha ntegrating Ce paration instr for hematolog alyzers CellaVi product at the 3, 2013. at together wi ellaVision's im ruments. The gy laboratorie ision DM96 an e IFCC-EFCC E ith its partner mage analysis product, DI-6 es with mediu nd CellaVision European Con r Sysmex the technology w 60, will be par um to large sa n DM1200. Sy ngress EuroMe company has with Sysmex c t of the Sysm ample volume ysmex is edLab 2013 in scell ex es n

On April 19 M position on M and Adminis MBA and has groups, with position was Magnus Blixt May 2, 2013. M stration funct s extensive ex h a focus on b s as Business D was appointe Magnus Blixt ion and will b xperience of r usiness perfo Demand Man ed as Chief Fin will have ove be part of the running smal ormance and p nager at SKF A nancial Office erall responsib managemen l and medium process impro AB. er (CFO) and w bility for the G t team. Magn m-sized comp ovement. His will take up hi Group's Finan nus Blixt holds anies in majo most recent s ce s an or

Financin ng

The funds at (61.5), of wh unutilized cr t the Group's ich SEK 52.5 m redit of SEK 5. disposal at th million (56.5) .0 million. he close of the was cash and e quarter cons d cash equival sisted of SEK lents. These fu 57.5 million unds include

The cash flow w from opera ating activities s for the quart rter was SEK 7 7.5 million (10 .0).

Total cash flo trade receiva ow for the pe ables. riod was SEK 6.3 (-0,3), wh ich was main ly due to the decrease in U f S m Unappropria funds SEK 57.5 million ated 5

C S Cash flow SEK 6.3

Parent company

Parent company sales in the quarter were SEK 30.0 million (37.0). The result before tax was SEK-1.2 million (6.6).

The parent company's investments in property, plant and equipment and intangible assets during the quarter amounted to SEK 3.1 million (1.7) and the cash flow was SEK 3.5 million $(-0.8)$ .

In other respects please refer to the information for the Group.

Personnel

The number of employees of the Group, restated as full-time equivalents, was 66 (64) at the close of the period. Of these, 38 (37) were men and 28 (27) women.

Other information

Group

On March 31, 2013 the Group consisted of the parent company and the wholly-owned subsidiaries CellaVision Inc. (USA), CellaVision Canada Inc. (Canada), CellaVision Japan K.K. (Japan) and CellaVision International AB.

Accounting policies

The consolidated accounts are prepared in accordance with International Financial Reporting Standards, IFRS. The interim report for the Group was prepared in accordance with IAS 34, Interim Financial Reporting, the Annual Accounts Act and in accordance with the Stockholm Stock Exchange rules and regulations for companies listed on NASDAQ OMX Stockholm. The interim report for the parent company was prepared in accordance with the Annual Accounts Act and the Swedish Financial Reporting Board recommendation RFR 2, Accounting for Legal Entities. The interim report has been prepared in accordance with the accounting policies and valuation methods presented in the Annual Report for 2012. New standards and interpretations that came into force on January 1, 2013 have not had any impact on CellaVision's financial reporting for the interim report period with the exception of the below reported changes.

IFRS 13 Fair value measurement

The new IFRS 13 applies to fair value measurement of both financial and non-financial items and replaces previous quidance contained in individual standards referring to fair value measurement. IFRS 13 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (the "exit price"). IFRS 13 has been applied prospectively from January 1, 2013. The application of IFRS 13 has not had any impact on the Group's results and financial position regarding the valuation of the Group's financial instruments.

IFRS 13 requires that several quantitative and qualitative disclosures should be presented in the financial statements in respect of fair value. As a result of these disclosure requirements in IFRS 13, IAS 34 Interim Financial Reporting was also updated.

IAS 1 Presentation of financial statements

As of 2013, an amendment to IAS 1 has been introduced which involves regrouping items presented in other comprehensive income into items that will be reclassified to profit or loss and items that will not be reclassified to profit or loss. CellaVision's application of the amendments to IAS 1 is presented in the Group statement of comprehensive income

Other new standards and interpretations that came into force on January 1, 2013 have not had any impact on CellaVision's financial reporting for the interim report period.

Number of employees 66

Financial ins struments

Derivatives h where fair va data for the a prices) or ind observable i rates for rem 2013. held for foreig alue is determ asset or liabil directly (i.e. de nformation re maining matur gn currency h mined on the b ity than listed erived from p eferring to ex rities. CellaVi edging are va basis of valua d prices are in prices). Curren xchange rates sion's derivat alued at level ation models b ncluded in lev ncy forwards a on the balan tives amount 2, financial in based on oth vel 1, either di are valued on nce sheet date to (1.2 million nstruments er observable rectly (i.e. as n the basis of e and market n) at March 31 e1,

The carrying fair value at M g amount of fi March 31, 201 nancial instru 13. uments measu ured at amort tized cost is c onsistent wit th

Segment rep porting

CellaVision's systems in th and balance s operations o he field of hem sheet regard only comprise matology, and ding operating e one operatin d therefore re g segment rep ng segment; a eference is ma porting. automated m ade to the inc icroscopy come stateme ent

Informatio on concern ning risks an nd uncerta ainties

Reduced dem risks. For a m refer to the r mand and cha more detailed risk and sensit anges in exch description o tivity analysis hange rates co of the risks an s in the Annua onstitute unc d uncertainti al Report for 2 certainties but es facing Cell 2012. t not material aVision, pleas l se

Review

This report h has not been r reviewed by t the company' 's auditors.

Financial c calendar

Annual Gene eral Meeting 2 2013:	April 24, 20 13
Interim repo ort January – J July:	July 17, 201 3
Interim repo ort January – S September:	October 24, , 2013
Year-end bu lletin 2013:	February 13 3, 2014

The interim r reports for 20 013 and annu al report for 2 2012 are avail able at www. .cellavision.co om.

The Board of company's a material risk Group are ex f Directors an and the Group s and uncerta xposed. nd the CEO ce p's business, f ainties to whic rtify that the financial posit ch the parent interim repor tion and perfo t company an rt fairly presen ormance and nd the compa nts the parent describes nies in the t

Lund, April 2 24, 2013

Lars Gatenbe eck Chairman of f the Board	Chr rister Fåhraeu us Mem mber of the Boa ard	Sven-Åk ke Henningss son Member r of the Board
Lars Henrikss son Member of th he Board	Rog ger Johanson Mem mber of the Boa ard	Torbjörn n Kronander Member r of the Board
Anna Malm B Bernsten Member of th he Board	Yvo onne Mårtens son Pres sident/CEO

Questions concerning the report can be addressed to:

Yvonne Mårtensson, CEO, CellaVision AB Tel: +46 708 33 77 82. Email: [email protected]

Sven-Åke Henningsson, Acting CFO, CellaVision AB Tel: +46 705 93 43 81. Email: [email protected]

Publication

The information in this interim report is disclosed by CellaVision AB (publ) pursuant to the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 24, 2013 at 2.00 pm.

Address

CellaVision AB (publ), corporate identity number: 556500-0998 Post: Ideon Science Park, SE 223 70 Lund, Visitors: Scheelevägen 19A, Ideon, Lund Telephone: +46 286 44 00, Fax: +46 46 286 44 70, Email: [email protected]

Web: www.cellavision.com, Blog: blog.cellavision.com, App: CellAtlas

CellaVision is listed on the NASDAQ OMX Stockholm, Small Cap list. The company is traded under the ticker symbol CEVI and ISIN code SE0000683484.

Consolidated d Income Stat tement in Sum mmary

All amount in ' 000 SEK	Jan-Mar 2013	Jan-Mar 2012	J Jan-Dec 2012
Net sales	33 795	40 415	169 512
Cost of goods sold	-11 817	-13 344	-59 456
Gross profit	21 978	27 071	110 056
Sales and marketing g expenses	-8 970	-9 194	-38 859
Administration expe enses	-6 902	-6 580	-29 060
R&D expenses	-6 791	-5 937	-21 435
Other operating inc come	-	-	-
Operating result	-685	5 360	20 702
Interest income and d financial exchange rate gains	78	79	225
Interest expense an nd financial exchange e rate losses	-891	-1 064	-2 376

Result before inco ome tax	-1 498	4 375	18 551
Tax	-	-1 732	-12 100
Net result	-1 498	2 643	6 451

Other comprehen nsive income:
Components not to o be reclassified to ne et profit:	-	-	-
Components to be reclassified to net pro ofit:
a) Financial assets a at fair value
Reclassified to oper rating result	-935	252	99
Revaluation of finan ncial assets	116	1 207	2 342
Income tax relating g to financial assets	180	-384	-537
b)Translation differe ence
Translation differen nce in the group	65	3	31
Sum of Component ts to be reclassified to o net profit:	-574	1 078	1 935
Sum of other comp prehensive income:	-574	1 078	1 935
Comprehensive re esult for the period d	-2 072	3 721	8 386

Jan-Mar 2013	Jan-Mar 2012	J Jan-Dec 2012
-0.06	0.11	0.27
5.15	5.44	5.24
70%	77%	70%
23 851 547	23 851 547	23 851 547
23 851 547	23 851 547	23 851 547
14.70	16.00	14.70

*/ In relation to net pro ofit and average outstand ding shares

Quarterly R Results

All amount in ' 00 00 SEK	Q1 2013	Q4 2012	Q3 2012	Q2 2012	Q1 2012	Q4 2011
Net sales	33 795	50 405	35 33 2	43 360	40 415	46 444
Gross profit	21 978	31 696	22 59 91	28 698	27 071	32 242
Gross margin in %	65	63	6 64	66	67	69
Overhead cost	-22 663	-24 882	-18 60 09	-24 152	-21 711	-25 296
Operating result	-685	6 814	3 98 82	4 546	5 360	6 946
Net result	-1 498	-3 194	3 89 92	3 110	2 643	7 349
Cashflow	6 296	-6 389	515 0	-8 996	-347	13 775

Consolidated Balance Sheet in Summary

All amount in '000 SEK	2013-03-31	2012-03-31	2012-12-31
Assets
Intangible assets	25 043	21 3 9 6	24 152
Tangible assets	3 2 3 7	2 1 7 7	2693
Deferred tax	37888	47 572	37 994
Financial assets	83	97	91
Inventory	15912	16 409	16 356
Trade receivables	31849	17716	40 632
Other receivables	9497	7768	10 402
Cash and bank	52 532	56 471	46 236
Total assets	176 041	169 606	178 556

Equity and liabilities
Equity	122840	129788	124 912
Short term debt	22 948	17 142	20802
Short term debt with interest	16 3 8 3	7 2 1 2	14 272
Trade payables	12014	13 264	16458
Other liabilities	1856	2 2 0 0	2 1 1 2
Total equity and liabilities	176 041	169 606	178 556

Consolidated statement of changes in equity

All amount in '000 SEK	2013-03-31	2012-03-31	2012-12-31
Balance at the beginning of the year	124 912	126 067	126 067
Dividend	$\overline{\phantom{0}}$		$-9541$
Net profit for the year	$-1498$	2 643	6451
Comprehensive result for the period	$-574$	1078	1935
Balance at the end of the year	122840	129 788	124 912

Cash Flow Analysis in Summary in Summary

All amount in '000 SEK	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Result before taxes	$-1498$	4375	18 5 5 1
Adjustment for items not included in cash flow	3690	-4748	7668
Taxes			$-790$
Cash flow from operations before changes in
working capital	2 1 9 2	-373	25 4 29

Changes in working capital	5 3 1 3	10 3 8 1	$-13936$
Cash flow from operations	7505	10 008	11 493

Capitalisation of development costs	$-2601$	$-1444$	$-9256$
Aquisitions in financial non-current assets	115	17	23
Aquisitions in tangible non-current assets	$-834$	$-421$	$-1854$
Cash flow from investment activities	$-3320$	$-1848$	$-11087$

New loans and instalments of dept	2 1 1 1	$-8,507$	$-1447$
Dividend	$\Omega$		$-9541$
Cash flow from financing activities	2 1 1 1	$-8507$	$-10988$

Total cash flow	6 2 9 6	-347	$-10582$

Liquid funds at beginning of period	46 236	56818	56818
Liquid funds at end of period	52 532	56 471	46 236

Income Statement - Parent Company

All amount in '000 SEK	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Net sales	29 9 74	37 043	161 949
Cost of goods sold	$-12790$	$-13336$	-78 322

Gross profit	17 184	23707	83 627

Sales and marketing expenses	$-3906$	$-3619$	$-15705$
Administration expenses	$-6901$	-6 580	$-29060$
R&D expenses	$-6791$	$-5937$	$-21435$
Other operating income

Operating result	$-414$	7571	17 427

Write-downs of shares in group companies
Interest income and financial exchange rate gain.	76	78	217
Interest expense and financial exchange rate loss	$-864$	$-1064$	$-2106$

Result before income tax	$-1202$	6585	15 538
Tax	$\Omega$	$-1732$	$-11408$
Net result	$-1202$	4853	4 1 3 0

Statement of Comprehensive Income

All amount in '000 SEK	Jan-Mar 2013	Jan-Mar 2012	Jan-Dec 2012
Net result for the period	$-1202$	4853	4 1 3 0
Other comprehensive income:
Sum of other comprehensive income:	0
Comprehensive result for the period	-1 202	4853	4 1 3 0

Balance Sheet - Parent Company

All amount in '000 SEK	2013-03-31	2012-03-31	2012-12-31
Assets
Intangible assets	25 043	21 3 9 6	24 152
Tangible assets	2 3 5 3	1743	2 1 2 6
Deferred tax	37 092	46 768	37 092
Financial assets	9852	9852	9852
Inventory	12 636	13725	12 286
Trade receivables	27 106	9963	31 840
Receivables from group companies	11 470	20 086	12 642
Other receivables	6789	5 640	7762
Cash and bank	45 772	48 138	42 301
Total assets	178 113	177 311	180 053

Equity and liabilities
Equity	130 208	141 673	131410
Short term debt
Short term debt with interest	17884	12 5 9 4	16086
Liabilities to group companies	16 383	7 2 1 2	14 272
Trade payables	11782	13 632	16 173
Other liabilities	1856	2 2 0 0	2 1 1 2
Total equity and liabilities	178 113	177311	180 053

This s is CellaV Vision

CellaVision's laboratories, hematology in the US, Ca s customers a , mainly in Eu companies. P anada and Jap re large and m rope and Nor Products are s pan. mid-sized hos rth America. I sold directly i spital laborato n most count n the Nordic ories and com tries sales are countries and mmercial via global d via subsidia ries

CellaVision's workflows an SEK 170 mill increase by a s analyzers rat nd competen ion, correspo at least 15 % a tionalize man ncy developm nding to an in annually over ual laborator ment within an ncrease of 9 % r an economic ry work and se nd between h %. The target c cycle. ecure and sup hospitals. In 20 is for sales to pport effectiv 012 sales wer continue to ve re

The product ts replace ma anual micros scopy in labo oratories for blood analys ses

After taking shows signs This analysis analyzer it m the sample, m of disease it i s is carried out must be done most blood te is examined f t automatical manually in a ests are first an urther to ena ly by CellaVis a microscope. nalyzed using ble it to be us sion's analyze . g cell counter sed as a basis r. Without Ce s. If the samp for diagnosis llaVision's ple s.

What is driv ving growth? ?

The demand assurance re Growing staf highly intere county coun coordinate g d for CellaVisio equirements i ff shortages in esting solutio ncil or hospita geographicall on's products n the healthc n laboratory o n. The trend i al groups and y spread serv s is strong and care market, p operations m s for more ho seek tools to vices. d is due to inc particularly in ake CellaVisio ospitals to join help them w creased efficie Europe and N on's automate n together an work more effe ency and qua North America ed products a d collaborate ectively and lity a. a e in

Five founda ations for gro owth

CellaVision's developmen for our analy s overall grow nt. Growth tak ytical method wth strategy is kes place thro d to be standa s based on glo ough focusing ard at clinical l obal expansio g on custome laboratories t on, partnershi rs and the ma throughout th p and produc arket. Our goa he world. ct al is

Target gro growing nee markets in A up and positio ed for automa Asia, mainly Ja oning. We cur ation. These a apan, China an rrently target are mainly fou nd South East clinical labora und in Europe t Asia. atories in hem e, North Amer matology with rica and select h a ted
Customer r through sati partners and quality, func score for reli from one to relations. Cust sfied custome d end custom ction and user ability and us five. tomers' purch ers can CellaV ers to ensure r-friendliness. ser-friendlines hasing behav Vision continu that our prod . In customer ss of the prod vior and needs ue to grow an ducts meet m surveys in the duct has been s direct our b nd develop. W market require e last two yea n just over fou usiness. Only We work close ements for ars the averag ur, on a scale to ge
Sales chan strong, strate through the and Abbott. continuous s looking at ne nels. CellaVisi egic and com largest hema Our own sale support and t ew opportun ion reaches a mplementary p atology comp es organizatio training to ou ities and form broad geogr partners with panies in the w ons in the Nor ur partners du ms of cooperat raphical mark a local prese world; Sysmex rdic area, the uring the sales tion. et by coopera nce. We sell o x, Beckman C USA, Canada s process. We ating with our products oulter, Sieme and Japan giv are constant ens ve ly
Product de groups and b the best solu developmen the market p evelopment. W by examining ution and pref nt through co puts further d We will grow b g the possibili ferably devel operation wit emands on o by broadening ty of commer op it ourselve th partners. T ur future prod g our product rcializing new es, but the str The emergenc duct develop t range for ex w areas of ana ategy also inc ce of competi pment. isting custom lysis. We seek cludes ng companie mer k es in
Company c important to culture. Satisfi o us that our e ied employee employees fee es create the c el involved an conditions fo nd motivated r satisfied cus d. Initiative an stomers. It is d responsibili ity

are importan in image ana of IT knowle nt factors beh alysis, artificia dge, we can d hind CellaVisio al intelligence develop solut on's positive d e and automat tions that brin development ted microsco ng considerab t. With leading py, as well as ble gains to ou g-edge exper a great quan ur customers. rtise ntity .

About Cella aVision's geo ographical m arkets

North Americ ca

North Ameri most import laboratories. world are pa solutions tha volumes. On sample volu Beckman Co CellaVision's ica is CellaVisi tant driver for . The growing articularly evid at ensure effe n top of the re mes are grow oulter and Siem s own sales or ion's most im r meeting gre g staff shortag dent in the US ective and sec equirements f wing due to th mens sell Cel rganization. In portant grow ater effective ges that exist SA and Canad cure managem for reduced la he ageing pop laVision's pro n Canada Cell wth market. Au eness requirem in laboratory da. Laboratori ment of large abor costs and pulation. The oducts in the U laVision sells d utomation ha ments in Nort y operations in ies are therefo and growing d shorter resp distributors S USA in paralle directly to the as long been t th American n the western ore seeking sample ponse times, Sysmex Amer el with e end custom the n rica, mer.

Europe, the M Middle East an nd Africa

Europe is Ce transition fro of years in th productivity distributors S Marketing w ellaVision's lar om manual m he European c y and offset th Sysmex, Siem work has just s gest market i microscopy to countries. The he coming yea mens, Beckma started in the n terms of the CellaVision's e laboratories ars' shortage o n Coulter and Middle East a e number of a method has b s are seeking s of biomedica d Abbott sell C and Africa. analyzers sold been in full sw solutions that al analysts. In E CellaVision's p d to date. The wing for a cou t can increase Europe the products. e uple e

Asia and the Pacific region n

CellaVision p and quality a long-term po sells via the d products are a assurance pot otential and d distributors S also appreciat tential. China demand is gra Sysmex, Sieme ted in Asia an , Hong Kong adually startin ens and Beckm nd the Pacific and South Ea ng to take off man Coulter. region for the ast Asia are m f. In most mar eir time-savin arkets with gr rkets CellaVisi ng reat ion

There are mo consists of a office in Chin ore than 20,0 bout 800 of C na with two e 00 hospitals i China's largest employees wh n China. The t hospitals. In ho support th target group n 2012 CellaVi e region's dis for CellaVisio sion establish stributors. on's products hed a market

Japan is a ma facing severa population t well able to s health care s company's t the distribut arket with im al challenges that at the sam solve quality sector. Since t echnology to tor Sysmex als portant grow with funding me time dem and efficiency the start in 20 o the thousan so sells CellaV wth potential f g problems as ands better q y problems ar 008 CellaVisio d or so major Vision's produ for CellaVisio s expenditure quality. Conse re highly inte n's subsidiari r clinical labor ucts. n. Japanese h increases for equently, prod eresting to the es have mark ratories in Jap health care is an ageing ducts that are e Japanese keted the pan. Since 201 e 10